A Combination of Pathway-Targeted Inhibitor with DNA-Repair Inhibitor: Preclinical Efficacy of Zactima and Olaparib in Triple Negative Subset of Breast Cancer.

被引：0
|
作者：
Dey, N. [1 ]
Wu, H. [1 ]
Sun, Y. [1 ]
De, P. [1 ]
Leyland-Jones, B. [1 ]
机构：
[1] Emory Univ, Atlanta, GA 30322 USA
来源：
CANCER RESEARCH | 2011年 / 71卷
关键词：
D O I：
10.1158/0008-5472.SABCS11-P3-18-02
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3-18-02
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Antitumor effect of a WEE1 inhibitor and potentiation of olaparib sensitivity by DNA damage response modulation in triple-negative breast cancer
    Ha, Dong-Hyeon
    Min, Ahrum
    Kim, Seongyeong
    Jang, Hyemin
    Kim, So Hyeon
    Kim, Hee-Jun
    Ryu, Han Suk
    Ku, Ja-Lok
    Lee, Kyung-Hun
    Im, Seock-Ah
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [32] Antitumor effect of a WEE1 inhibitor and potentiation of olaparib sensitivity by DNA damage response modulation in triple-negative breast cancer
    Dong-Hyeon Ha
    Ahrum Min
    Seongyeong Kim
    Hyemin Jang
    So Hyeon Kim
    Hee-Jun Kim
    Han Suk Ryu
    Ja-Lok Ku
    Kyung-Hun Lee
    Seock-Ah Im
    Scientific Reports, 10
  • [33] Rational drug combination therapy for improved efficacy and delayed resistance in triple negative breast cancer.
    Gilani, Rabia
    Lachacz, Eric
    Bao, Li Wei
    Phadke, Sameer
    Soellner, Matthew
    Merajver, Sofia
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [34] In vivo preclinical evaluation of the topoisomerase I inhibitor camptothecin in human triple negative breast cancer xenografts
    Nemati, F.
    Dieras, V.
    de Plater, L.
    Berniard, A.
    Assayag, F.
    Elbaz, C.
    Fontaine, J. J.
    Vincent-Salomon, A.
    Marangoni, E.
    Decaudin, D.
    EJC SUPPLEMENTS, 2010, 8 (05): : 39 - 39
  • [35] mTOR Pathway Inhibitor Nanoparticles Beneficially Modulate Autophagy in Triple Negative Breast Cancer Cells
    Bibee, K. P.
    Li, A. J.
    Wickline, S. A.
    CANCER RESEARCH, 2010, 70
  • [36] Decreased Fanconi anemia gene expression contributes to efficacy of PARP and DNMT inhibitor combination therapy in triple negative breast cancer
    McLaughlin, Lena J.
    Li, Huili
    Nagaria, Pratik
    Baylin, Stephen B.
    Zahnow, Cynthia A.
    Rassool, Feyruz V.
    CANCER RESEARCH, 2017, 77
  • [37] Combination of androgen receptor inhibitor enzalutamide with the CDK4/6 inhibitor ribociclib in triple negative breast cancer cells
    Choupani, Edris
    Madjd, Zahra
    Saraygord-Afshari, Neda
    Kiani, Jafar
    Hosseini, Arshad
    PLOS ONE, 2022, 17 (12):
  • [38] Metronomic low dose cyclophosphamide in combination with a DNA methyltransferase inhibitor limits tumor growth in murine triple negative breast cancer
    Camarena, Carmen
    Smith, Timothy M.
    Bear, Harry
    Martin, Rebecca
    JOURNAL OF IMMUNOLOGY, 2020, 204 (01):
  • [39] Antitumoral activity of EC70124, a novel multitarget kinase inhibitor, in triple negative breast cancer.
    Cuenca-Lopez, Maria D.
    Carlos Montero, Juan
    Serrano-Heras, Gemma
    Corrales-Sanchez, Veronica
    Morales, Jorge
    Moris, Francisco
    Pandiella, Atanasio
    Ocana Fernandez, Alberto
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [40] Identification of optimal combination therapy partners for PI3K/Akt/mTOR pathway inhibitor in triple negative breast cancer
    Shariati, M.
    Paez-Arango, N.
    Bristow, C. A.
    Evans, K. W.
    Peoples, M. D.
    Carugo, A.
    Heffernan, T. P.
    Meric-Bernstam, F.
    CANCER RESEARCH, 2019, 79 (04)
12345